Intelligent Bio Solutions Inc. (INBS)vsNovartis AG ADR (NVS)
INBS
Intelligent Bio Solutions Inc.
$2.05
-0.97%
HEALTHCARE · Cap: $7.48M
NVS
Novartis AG ADR
$138.99
-0.27%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1344866% more annual revenue ($56.69B vs $4.22M). NVS leads profitability with a 22.5% profit margin vs -294.9%. NVS earns a higher WallStSmart Score of 51/100 (C-).
INBS
Hold36
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-9.6%
Fair Value
$4.79
Current Price
$2.05
$2.74 premium
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$138.99
$45.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 35.8% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -170.2% — below average capital efficiency
Negative free cash flow — burning cash
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : INBS
The strongest argument for INBS centers on Price/Book, Revenue Growth. Revenue growth of 35.8% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : INBS
The primary concerns for INBS are EPS Growth, Market Cap, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
INBS profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.
INBS carries more volatility with a beta of 4.21 — expect wider price swings.
INBS is growing revenue faster at 35.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 36/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Intelligent Bio Solutions Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Intelligent Bio Solutions Inc. (INBS) is a pioneering biotechnology company focused on delivering cutting-edge diagnostic solutions and biomarker-driven technologies, specifically designed for drug abuse testing and monitoring. Utilizing advanced scientific methodologies, INBS offers rapid and precise testing options that enhance clinical decision-making processes and improve patient outcomes. In a healthcare landscape increasingly reliant on innovative diagnostic tools, INBS is well-positioned to make substantial contributions to this evolving field, reinforcing its dedication to advancing healthcare quality and operational effectiveness.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?